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Abstract. The presence of tumor cells in the bone marrow (BM) 
could be relevant to identifying high risk of disease progression 
and death in gastrointestinal cancer. However, the molecular 
profile associated with disseminated tumor cells (DTCs) homing 
to the BM has yet to be defined. MicroRNAs (miRNA) play 
key roles in cellular processes implicated in cancer. Thus, we 
investigated in 38 patients with colorectal, gastric or pancreatic 
cancer whether the presence of BM-DTCs is associated with 
a specific miRNA tumor profile and analyzed their potential 
prognostic impact. DTCs were detected by immunocytochem-
istry and anti-cytokeratin antibodies in 42.1% of the patients. 
miRNAs were isolated from formalin-fixed, paraffin-embedded 
tumors. qRT-PCR was used for miRNA profiling. No significant 
associations were found among DTC detection and miRNA 
deregulation. Kaplan-Meier curves demonstrated significantly 
reduced progression-free survival (PFS) and overall survival 
(OS) in the DTC-positive patients. Although miR-21 was upreg-
ulated in 90.6% of the tumors, no associations with outcomes 
were found. miR-17 and miR-20a (miRNA-17-92 cluster) were 
upregulated in 33.3 and 42.4%, respectively. Upregulation of both 
was correlated and found in 30.3%. Univariate analysis shows 
that increasing values for miR-20a were significantly associated 
with reduced PFS (HR 1.022; p=0.016) and OS (HR 1.027; 
p=0.003). In multivariate Cox models, DTC positivity (HR 4.07; 
p=0.005) and miR-17 overexpression (HR 2.11; p=0.003) were 
significantly associated with a higher risk of disease progression. 
The presence of DTCs in the BM (HR 3.98; p=0.010) and a 
miR-17 overexpression (HR 2.62; p<0.001) were also associ-
ated with a risk of death. Our study suggests that the presence 
of BM-DTCs and the upregulation of the miR-17-92 cluster in 
tumors are both significant but independent prognostic markers 
in gastrointestinal cancer patients.
Introduction
Cancers of the gastrointestinal (GI) tract are a leading cause 
of cancer-associated morbidity and mortality across the world. 
The predicted numbers of deaths in 2011 in the European 
Union (1) due to GI cancer are 162,026 deaths for colorectal 
cancer, followed by 69,304 deaths for pancreatic cancer and 
62,340 deaths for stomach cancer. Although multimodal thera-
pies, including improved local treatments, chemotherapy and 
molecular-targeted agents, have recently been introduced in the 
clinical care of GI cancer patients, better staging and prognostic 
factors to guide treatment decisions are clearly required.
Well-characterized biomarkers are needed to personalize 
therapy and to predict metastatic progression. Tumor seeding 
is considered an early event in the process of metastasis forma-
tion. Therefore, the detection of these disseminated tumor cells 
(DTC) in distant organs such as the bone marrow (BM) could be 
important to identify patients at a high risk of disease progres-
sion and death and might indicate the need for further therapeutic 
approaches (2). Although significant associations with relapse 
and survival have been reported (3-12), the prognostic relevance 
of the detection of BM-DTC in GI cancer patients is controversial 
(13-15). However, the biological characteristics and proliferative 
potential of this DTC are poorly understood (16). The identifica-
tion and characterization of molecules that control cancer cell 
spread in distant organs is critical to our understanding of cancer 
dissemination. The molecular profile that links the biologic char-
acteristics of primary GI tumors with the presence of epithelial 
cells homing to bone marrow has yet to be defined.
Tumor progression and metastasis development are complex 
processes that involve the activation of oncogenes, functional 
loss of tumor suppressor genes and microRNA (miRNA) 
deregulation (17). Mature miRNAs are single-stranded, non-
coding RNAs that are involved in many biological pathways. 
miRNA regulation plays key roles in various cellular processes 
commonly implicated in cancer, such as differentiation, cell 
growth, angiogenesis, epithelial-to-mesenchymal transition 
(EMT) and invasion. An increasing number of studies analyzing 
Prognostic impact of disseminated tumor cells and 
microRNA-17-92 cluster deregulation in gastrointestinal cancer
MANUEL VALLADARES-AYERBES1,2,  MOISES BLANCO2,  MAR HAZ2,  VANESSA MEDINA2,   
PILAR IGLESIAS-DÍAZ3,  MARIA J. LORENZO-PATIÑO3,  MARGARITA REBOREDO1,   
ISABEL SANTAMARINA2,  ANGÉLICA FIGUEROA2,  LUIS M. ANTÓN-APARICIO1,4  and  LOURDES CALVO1
1Medical Oncology, University Hospital; 2Biomedical Research Institute INIBIC; 3Pathology, 
University Hospital; 4Medicine Department, La Coruña University, UDC, Spain
Received March 22, 2011;  Accepted May 13, 2011
DOI: 10.3892/ijo.2011.1112
Correspondence to: Dr Manuel Valladares-Ayerbes, Medical Onco-
logy, La Coruña University Hospital, Servicio Galego de Saúde 
(SERGAS), As Xubias 84, CP. 15006, La Coruña, Spain
E-mail: manuel.valladares.ayerbes@sergas.es
Key words: gastrointestinal cancer, disseminated tumor cells, micro-
RNA, prognostic, real-time PCR
VALLADARES-AYERBES et al:  DISSEMINATED TUMOR CELLS AND miRNA IN GASTROINTESTINAL CANCER1254
miRNA expression profiles in gastrointestinal tumors and their 
potential clinical relevance have been reported (18-25).
miR-21 is upregulated in different tumor types, including 
lung, breast, prostate, pancreatic, and colorectal cancer (17). In 
colorectal cancer, high expression of miR-21 is correlated with 
poor survival, poor therapeutic outcome (19), and development 
of distant metastasis (20). Overexpression of miR-21 has been 
included in a seven-miRNA signature that was able to predict 
relapse-free survival and overall survival (OS) in gastric cancer 
patients (21). In pancreatic cancer, high miR-21 expression is 
associated with shorter survival (22) and can predict outcomes 
in resectable patients treated postoperatively (23).
miR-20a and miR-17 belong to the miR-17-92 miRNA 
cluster, a family of oncogenic miRNAs commonly deregulated 
in cancer (24). miR-20a and miR-17 are upregulated in colorectal 
(18,19,25), gastric (21,25), and pancreatic (25) adenocarci-
nomas. However, miR-17-92 miRNA cluster deregulation in GI 
cancer and its relationship with prognosis are poorly defined.
In the present study, our aims were to investigate whether 
the presence of BM micrometastasis, detected by a standard-
ized immunocytochemical method, is associated with a specific 
miR-21, miR-20a and miR-17 tumor profile, which could serve 
as a prognostic factor in gastrointestinal cancer patients.
Patients and methods
Patient data. Consecutive patients with GI cancer from the 
Medical Oncology Unit at University Hospital in La Coruña 
(Spain) were prospectively included in the study. Inclusion 
criteria were as follows: confirmed pathological diagnosis of 
invasive adenocarcinoma of the GI tract, including colorectal, 
gastric and pancreatic tumors; stage I-III cancer with no prior 
systemic therapy for GI cancer; stage IV cancer without previous 
systemic therapy or with confirmed cancer progression after such 
treatment; and provision of written informed consent. Exclusion 
criteria were defined as follows: any other previous malignancy, 
coagulation disorders, platelet count less than 20.0x109 L-1, and 
any previous systemic therapy for cancer except stage IV patients 
with progressive disease confirmed at the time of BM sampling.
The diagnostic work-up included a clinical examination, 
blood sampling with CA 19.9 and CEA serum determination, 
an endoscope (when clinically indicated), a chest X-ray and 
computed tomography (CT) scan of the abdomen and pelvis. 
Chest CT was performed on the upper digestive tract, rectal 
tumors and stage IV patients. Patients were followed to observe 
disease progression, with imaging every 6-12 weeks.
Serum CEA (with an upper limit of normal of 5 ng/ml) 
and CA 19.9 (with an upper limit of normal of 37 U/ml) levels 
were determined using enzyme immunoassay test kits (Advia 
Centaur, Siemens Healthcare Diagnostics), according to the 
manufacturer's instructions.
After informed, written consent was obtained from each 
patient, BM aspiration was performed under local anesthesia, 
just before systemic treatment for pathological confirmed GI 
cancer. In patients who first underwent surgery as loco-regional 
treatment for primary disease, BM aspirate was obtained 
after the operation. Otherwise, BM samples were obtained 
before neo-adjuvant chemotherapy or in the presence of active 
metastatic disease. BM was aspirated from anterior or poste-
rior iliac crest unilaterally. A skin incision was made to avoid 
contamination with epidermal cells. The study was approved 
by the Institutional Review Board of the Ethics Committee of 
Clinical Investigation of Galicia (Spain), and written informed 
consent was obtained from all patients.
Pathological analysis. Primary tumors, regional lymph nodes 
and tissues collected during surgery were processed on a routine 
diagnostic basis. Histological tumor type, depth of tumor inva-
sion and nodal involvement were analyzed, and the disease was 
staged and graded according to the TNM/UICC system (26). 
Vascular and perineural invasion were analyzed. When surgery 
was not performed, pathologic diagnosis was obtained using 
endoscope- or radiological-guided biopsy.
Residual disease status at the time of BM aspiration was clas-
sified as R0 when no residual disease was present after surgery, 
R1 when microscopic residual disease was found, and R2 in the 
presence of macroscopic disease. Patients from whom BM was 
obtained before the start of neo-adjuvant systemic treatment 
were categorized as R2.
Preparation of the bone marrow. Unilateral BM aspiration was 
performed from anterior or posterior iliac crest under local 
anesthesia and transferred into heparinized tubes. Mononuclear 
cells (MNCs) were separated by density-gradient centrifugation 
using Lymphoprep (Nycomed, Oslo, Norway). MNCs were 
collected from the interphase layer and washed twice in PBS 
with 10% FCS. Cytospins were prepared (5x105 MNCs/slide) 
on polylysine-coated slides in a Hettich cytocentrifuge. The 
cytospins were air-dried at RT overnight before freezing at -80˚C 
or immunostaining.
Immunocytochemical staining. Immunocytochemistry (ICC) 
was performed as described previously (27) using the Vectastain 
ABC-AP kit (Vector), according to the manufacturer's instruc-
tions. Slides (5x105 BM MNCs) were incubated with the 
anti-cytokeratin (CK) monoclonal antibodies AE1/AE3 (Dako). 
At least two slides were incubated with a negative control 
antibody of the same immunoglobulin isotype (IgG1). The visu-
alization stage included use of a Vector Red alkaline phosphatase 
substrate kit. Endogenous alkaline phosphatase activity was 
inhibited by addition of levamisole. The slides were counter-
stained with Gill's hematoxylin to visualize nuclear morphology. 
The slides were manually screened by light microscopy by two 
pathologists (PID, MLP) with no knowledge about clinical or 
follow-up data. All of the stained cells were closely evaluated. 
Categorization of CK-positive cells was performed according 
to the recommended guidelines (28). The presence of DTC was 
recorded as positive when at least one stained cell exhibited 
typical tumor cell morphology or when this immunostained cell 
lacked hematopoietic characteristics and was not found in nega-
tive controls.
microRNA isolation and qRT-PCR in tumor tissue. microRNA-
enriched total RNA was isolated from formalin-fixed, 
paraffin-embedded (FFPE) tumor and normal colonic mucosa 
samples using the Recover All Total Nucleic Acid Isolation 
Kit for FFPE Tissues (Ambion/Applied Biosystems, USA), 
following the manufacturer's instructions.
The mirVana qRT-PCR miRNA Detection Kit and the 
corresponding mirVana qRT-PCR primer sets (Ambion/Applied 
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Biosystems, USA) were used to detect and quantify miR-17 
and miR-20a. Results were normalized using 5S rRNA and U6 
snRNA (mirVana qRT-PCR Primer Sets for Normalization; 
Ambion/Applied Biosystems).
miR-21 was detected and quantified using a miRCURY LNA 
First-Strand cDNA Kit, miRCURY LNA SYBR Green Master 
Mix and specific miRCURY LNA Primer Sets (Exiqon, USA). 
Mircury LNA Endogenous Control Primer Sets for 5S and U6 
(Exiqon) were used as reference genes.
miRNAs were amplified and detected in a LightCycler 
480 (Roche, Germany) real-time thermal cycler, using SYBR 
Green dye. Melting curves were generated using the LightCycler 
analysis software to determine whether there were spurious 
amplification products (29).
The relative expression software tool (REST) was used 
to analyze the relative miRNA expression in each tumor and 
control sample (non-tumor colonic tissue) and to determine 
the fold-difference for miR-17, miR-20a and miR-21 (30). 
The expression levels of target miRNAs were standardized 
by an index containing 5S rRNA and U6 snRNA. The REST 
program is based on the correction for exact PCR efficiencies 
and the mean crossing point deviation between sample group(s) 
and control group(s). Subsequently, the expression ratio results 
of the investigated transcripts were tested for significance by a 
pair-wise fixed reallocation randomization test and plotted using 
standard error (SE) estimation using a complex Taylor algorithm. 
miRNA analyses were performed with no knowledge about 
clinical or follow-up data.
Study design and statistical analysis methods. Differences in 
the distribution of variables between patient groups according 
to the presence of DTC in BM were assessed by Pearson's χ2 test, 
Fisher's exact test or the Kruskal-Wallis test. Non-normality of 
the distribution of miRNA expression values was confirmed by 
the Kolmogorov-Smirnov test. Thus, non-parametric statistics 
(Mann-Whitney and Kruskal-Wallis tests) were used to analyze 
the potential correlation between miRNA expression and the 
clinical and pathological features of the study subjects.
Logistic regression analyses were used to assess the effect 
of tumor miRNA levels on the risk of DTC detection in BM. 
Odds ratios (OR) and 95% confidence intervals (CI) were 
estimated.
Progression-free survival (PFS) was measured as the time 
between the baseline BM sampling for DTC analysis and the 
documentation of first tumor progression based on clinical and 
radiological studies, second tumor or death (events). OS was 
measured from the time baseline BM was obtained to the date 
of death from any cause or date of last follow-up. Patients who 
were alive and progression-free at the time of analysis were 
censored by using the time between the BM assessment and 
their most recent follow-up evaluations. The distribution of 
time-to-event end points, namely PFS and OS, were estimated 
using the Kaplan-Meier method and compared using the log-
rank test.
Multivariate survival analyses (PFS and OS) were performed 
with Cox proportional hazard regression models. We estimated 
hazard ratios (HRs), 95% CI and p-values. All statistical tests 
were two-sided, and p-values <0.05 were considered statisti-
cally significant. SPSS software (version 16.0) was used for data 
analysis.
Results
Patient characteristics. From February 2002 to January 2003, 
38 GI cancer patients were included. Clinical characteristics are 
shown in Table I. Surgery was performed in 30 patients before 
Table I. Patients and clinicopathological characteristics.
  N %
Age (years)
 Mean (SD, range) 62.5 (7.9, 45-76)
 <65 years 21 55.3
 ≥65 years 17 44.7
Gender  
 Female 13 34.2
 Male 25 65.8
Primary tumor site  
 Colon or rectum 28 73.7
 Stomach   7 18.4
 Pancreas   3   7.9
Stage  
 I-II   6 15.8
 III   9 23.7
 IV 23 60.5
pT  
 pT1-pT2   5 13.1
 pT3 22 57.9
 pT4   8 21.1
 pTx   3   7.9
 pN0 14 36.8
 pN1 12 31.6
 pN2   7 18.4
 pNx   5 13.2
M 
 M0 15 39.5
 M1 23 60.5
R status  
 R0-R1 13 34.2
 R2 25 65.8
Location of metastasis  
 Liver   8 34.8
 Extra-hepatic metastasis   8 34.8
 Liver and extra-hepatic   7 30.4
Grade  
 Low grade 15 39.5
 High grade 23 60.5
Vascular/perineural invasion  
 Yes 18 47.4
 No 11 28.9
 Unknown   9 23.7
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BM sampling. Median time from surgery to BM aspiration was 
7 weeks (mean 26.8; standard error: 7.2; range 3-162 weeks).
BM aspiration was obtained after R0 or R1 surgery in 13 
patients. In this subgroup, 69.2% of the patients suffered PFS 
events. In 25 patients, BM samples were obtained before neo-
adjuvant chemotherapy or in the presence of active metastatic 
disease, both of which were categorized as R2 at the time of BM 
aspiration. In this subgroup, PFS events were found in 92% of 
patients (Fisher's exact test, p=0.154).
All patients were followed up until death or the end of the 
study. The mean follow-up time was 153 weeks (standard error 
21.4; median 108.5 weeks; range 2-388 weeks). Progression 
events were detected in 32 patients (84.2%); 27 patients died 
(71.1%). The median PFS was 37 weeks (standard error 9.2; 
95% CI: 18.9-55.1). The median global survival was 137 weeks 
(standard error 44.5; 95% CI: 49.9-224.1).
Cytokeratin immunocytochemistry. Isolated tumor cells in BM 
were detected using anti-CK monoclonal antibodies AE1/AE3 
and standardized morphological criteria (28). At least 2x106 BM 
MNC cells were screened per patient. DTC was found in BM in 
16 patients (42.1%, standard error: 0.08). The numbers of tumor 
cells detected were: 1 (five patients), 2 (seven patients), 3 (two 
patients), 15 (one patient) and 22 (one patient).
Previous surgery was not related to the presence of DTC in 
BM (Fisher's exact test, p=0.698). To explore the possible influ-
ence of the time elapsed from the most recent surgery on the 
presence of DTC, we analyzed the detection of DTC according 
to time interval from the operation and BM sampling. The 
median time from surgery to BM was 26.8 weeks ± 7.2 weeks 
(SEM) (median, 7 weeks; range, 3-162). The 25th percentile was 
5 weeks. There was no significant difference in DTC detection 
between time intervals (≤5 or >5 weeks) from the last surgery 
(50 and 36.4%, respectively, Fisher's exact test, p=0.678).
Bone marrow DTC and correlations with clinicopathology. 
Clinical and pathologic characteristics of the patients and 
associations with the detection of DTC in BM are shown in 
Table II. The detection of DTC was not associated with any of 
the parameters analyzed.
However, Kaplan-Meier survival analyses demonstrated 
significantly reduced PFS and OS among the DTC-positive 
patients (Fig. 1). The median PFS was 40 weeks (95% CI: 12.4-
67.6) for the patients without DTC versus 29 weeks (95% CI: 
0-60.4) for the subgroup positive for DTC in BM (log-rank; 
p=0.026). The median OS was 165 weeks (95% CI: 93.9-236 
weeks) in patients without DTC. In contrast, OS was significantly 
reduced (median 75 weeks; 95% CI: 22.8-127.2 weeks) in those 
patients with CK-positive cells in BM (log-rank test; p=0.045. 
When only stage I-III patients were considered, the presence of 
DTC in BM defined a subgroup with a lower median survival 
(137 weeks vs. not reached; log-rank; p=0.038).
miRNA expression in tumors. microRNA-enriched total RNA 
was retrieved from 33 FFPE-tumor samples for miR-17 and 
miR-20a analysis and from 32 specimens for miR-21 analysis. 
Expression of miR-17, miR-20a and miR-21 showed a right-
skewed distribution over the patient population (Fig. 2). Mean 
relative expression levels were 10.1 (SEM 3.4; range 0-89.4) for 
miR-17, 12.7 (SEM 4.2; range 0-110.3) for miR-20a and 24.3 
Table II. Distribution of clinicopathological parameters and 
disseminated tumor cells in bone marrow.
 DTC positive ----------------------------------
Parameter N % P-value
Age (years)   0.917
 <65   9 42.9
 ≥65   7 41.2
Gender   0.715
 Male 10 40
 Female   6 46.1
Primary tumor site   0.267a
 Colon or rectum 10 35.7
 Stomach/pancreas   6 60
Stage   0.683b
 I-II   2 33.3
 III   3 33.3
 IV 11 47.8
pT   0.141a
 pT1-T2   4 80
 pT3-T4 11 57.9
pN   0.142
 Node negative   8 57.1
 Node positive   6 31.6
R status   0.743
 R0-R1   5 38.5
 R2 11 44
Location of metastasis   0.675b
 None   5 33.3
 Liver   7 46.7
 Non-liver metastasis   4 50
Grade   0.071
 Low grade   9 60
 High grade   7 30.4
Vascular/perineural invasion   1.000
 No   5 45.4
 Yes   7 38.9
Ca 19.9   0.850
 ≤37 10 41.7
 >37   5 38.5
CEA   0.461
 ≤5 10 45.4
 >5   5 33.3
P-value computed by Pearson's χ2 test. aP-value computed by Fisher's 
exact test. bP-value computed by Kruskal-Wallis test.
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(SEM 4.6; range 0.5-100.8) for miR-21. In tumors, miR-17 and 
miR-20a were highly co-expressed (Spearman correlation coef-
ficient 0.650; p<0.001). No correlations were found between 
miR-21 and miR-17 (p=0.476) or miR-20a (p=0.362) expression.
Two different strategies were used to categorize relative 
expression levels for each miRNA in every tumor sample. First, 
a miRNA was considered up-regulated when the relative expres-
sion level was higher than the mean value in the tumor cohort. 
Using this approach, miR-17 and miR-20a were overexpressed 
in 27.3% (9/33) and 21.2% (7/33) of tumors, respectively. miR-21 
was overexpressed in 40.6% of patients (13/32).
In the second strategy, REST was used as described in 
Patients and methods (30). The REST output tells the user if 
the expression ratio results of the investigated targets are up- or 
down-regulated in the sample group (tumor) in comparison with 
the control group (non-tumor colonic tissue). Differences in 
expression between tumor samples and controls were assessed for 
statistical significance at p-values ≤0.01 by a randomization test. 
Using REST, miR-21 was up-regulated in 90.6% (29/32) of the 
tumors. The REST analysis indicated that miR-17 and miR-20a 
were up-regulated in 33.3% (11/33) and 42.4% (14/33) of tumors, 
respectively. Up-regulation of both miR-17 and miR-20a was 
found in 10 patients (30.3%; Fisher's exact test, p<0.001).
Figure 1. Kaplan-Meier curves depicting progression-free survival (A) and 
overall survival (B) depending on the detection of disseminated tumor cells in 
bone marrow. p-values were calculated with the log-rank test. 
Figure 2. Distribution of (A) miR-17, (B) miR-20a and (C) miR-21 expression 
in tumors. Frequencies of expression are plotted as a function of the expression 
values. A continuous line was added to indicate the normal distribution. Mean, 
SEM and range of miRNA expression values are indicated. 
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Table ΙΙΙ. MiRNA expression according to the clinical and pathologic characteristics of the patients.
 miR-17 miR-20 miR-21
 --------------------------- --------------------------- ---------------------------
  N Mean SEM P-value Mean SEM P-value Mean SEM P-value
Age (years)    0.605   0.334   0.317
 <65 years 19 13.69 5.59  18.46   6.87  28.98 7.07
 ≥65 years 14   5.22 2.49  4.9   2.08  16.93 5.15
Gender    0.474   0.837   0.876
 Male 21 10.83 4.8  14.92   6.32  23.7 5.05
 Female 12   8.81 4.51  8.84   3.22  25.3 9.12
Primary tumor site    0.983   0.799   0.883
 Colon or rectum 23 10.54 4.25  9.79   3.63  23.34 5.53
 Stomach/pancreas 10   9.07 5.99  19.44 11.11  24.22 8.53
Stage    0.386a   0.963a   0.449a
 I-II 6 10.87 7.21  8.80   6.34  13.85 6.29
 III 8   4.51 3.97  6.80   3.41  21.56 7.62
 IV 19 12.20 5.30  16.43   6.82  28.63 6.84
pT    0.415   0.559   0.686
 pT1-pT2 5 14.69 9.03  15.19   7.61  38.24 19.26
 pT3-pT4 25   8.44 3.85  12.41   5.24  23.64 4.52
pN    0.459   0.080   0.464
 Negative 13   3.78 2.44  2.78   1.47  32.67 9.02
 Positive 15 12.21 6.25  20.12   8.33  24.07 5.84
M    0.203   0.827   0.388
 M0 14   7.23 3.76  7.66   3.21  17.99 4.94
 M1 19 12.2 5.3  16.43   6.82  28.63 6.84
Location of metastasis    0.439a   0.966a   0.474a
 None 14   7.23 3.76  7.66   3.21  17.99 4.95
 Liver 11 16.46 8.81  15.88   7.29  34.36 10.19
 Non-liver metastasis 8   6.36 3.24  17.20 13.40  20.74 8.16
R status    0.052   0.911   0.173
 R0-R1 12   3.00 2.66  13.65   9.1  29.56 7.93
 R2 21 14.15 5,00  12.18   4.21  21.15 5.58
Grade    0.747   0.311   0.527
 Low grade 13   7.1 3.21  5.70 2.36  19.75 6.42
 High grade 20 12.03 5.27  17.27 6.59  27.69 6.35
Vascular/perineural invasion    0.845   0.429   0.38
 No 10   6.51 3.75  17.3 10.71  27.38 10.12
 Yes 14 10.28 6.57  10.18   5.76  31.70 6.66
Serum tumor markers         
 Ca 19.9 >37 13 11.56 5.26 0.116 18.97 10.01 0.487 12.18 3.22 0.071
 CEA >5 15 21.82 8.67 0.017 28.95 10.85 0.137 19.58 7.45 0.155
Mean values and standard error (SEM) for miRNA expression in subgroups are shown. Mann-Whitney test, 2-sided. aKruskal-Wallis test.
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Associations of deregulated miRNAs with clinical outcome. 
miRNA expression according to clinical and pathologic charac-
teristics is listed in Table III. Only increased serum CEA level 
was associated with high miR-17 tumor expression (p=0.017). 
Otherwise, no significant associations were found among 
miRNA tumor expression and any of the clinical or pathologic 
parameters analyzed. A trend was observed between high 
expression of miR-17 and macroscopic residual tumor (R2) at 
the time of BM sampling (p=0.052), suggesting a more aggres-
sive clinical presentation. Also, a trend was observed between 
miR-20a expression and lymph node metastasis (p=0.08). 
Likewise, a trend between miR-21 tumor expression and serum 
CA 19.9 level was found (p=0.071).
To verify the association between miRNA expression and 
survival (PFS and OS), the miRNA expression data were dichot-
omized into clearly defined high and low expression groups. This 
cutoff was set based on REST as described above. Mean values 
(with SEM) in the low and high expression groups, respectively, 
for each miRNA were as follows: 0.09 (0.05) and 30.1 (7.24) 
for miR-17 (p<0.001); 0.37 (0.33) and 29.45 (7.97) for miR-20a 
(p<0.001); 0.8 (0.23) and 26.74 (4.82) for miR-21 (p=0.005).
Kaplan-Meier curves for patients categorized according to 
miRNA expression are shown in Fig. 3. The median PFS for the 
group with high miR-17 expression and the other group without 
miR-17 up-regulation were 31 weeks and 49 weeks, respectively 
(Fig. 3A; p=0.026). In addition, the differences in median OS 
Figure 3. Kaplan-Meier curves depicting progression-free survival (PFS) and overall survival (OS) depending on the tumor miRNA expression. PFS according 
miR-17 expression (A). PFS according miR-20a expression (B). PFS according miR-21 expression (C). OS according miR-17 expression (D). OS according miR-20a 
expression (E). OS according miR-21 expression (F). p-values were calculated with the log-rank test.
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according to miR-17 values (55 weeks for the up-regulated group 
and 192 weeks for the low miR-17 group) were also significant 
(Fig. 3D; p=0.004). However, Kaplan-Meier estimates of PFS 
and OS were not significantly correlated with up- or down-
regulation of miR-20a and miR-21 in tumors (Fig. 3).
HRs for PFS and OS were estimated considering the actual 
values of every miRNA as a continuous variable in the Cox 
regression model. Across the entire cohort, increasing values 
for miR-20a were associated with PFS events (HR 1.022; 95% 
CI: 1.004-1.040; p=0.016) and reduced OS (HR 1.027; 95% CI: 
1.009-1.046; p=0.003). When adjusting for TNM/UICC stage as 
covariate in the Cox model, increasing values for miR-20a and 
miR-17 were associated with the risk of progression and death 
in stage I-III patients. The estimated HRs for miR-20a levels 
were 1.063 (95% CI, 1.002-1.127; p=0.043) and 1.065 (95% CI, 
1.003-1.130; p=0.040) for PFS and OS, respectively. For miR-17, 
increased values were also significantly associated with risk 
of progression (HR 1.056; 95% CI, 1.007-1.107; p=0.024). The 
estimated HR for miR-17 values and OS was 1.065 (95% CI, 
0.999-1.102; p=0.052).
No significant associations were found between actual 
miR-21 values for the entire cohort and PFS (HR 1.007; 95% 
CI, 0.993-1.022; p=0.346) or OS (HR 1.0; 95% CI, 0.983-1.017; 
p=0.988). Moreover, in stage I-III patients, hazard ratios for 
increasing miR-21 values and PFS (HR 1.005; 95% CI, 0.966-
1.045; p=0.821) or OS (HR 0.985; 95% CI, 0.939-1.032; p=0.52) 
were not significant.
miRNA deregulation in tumors and bone marrow DTC. We 
analyzed whether the tumor expression levels of miR-17, miR20a 
and miR-21 were associated with the presence of DTC in BM. 
In DTC-positive patients, the mean miR-17 value in tumors was 
4.89 (SEM 2.8), which was not significantly different (p=0.43) 
from those who were DTC-negative (13.9; SEM 5.5). The mean 
value of miR-20a in tumors from the patients positive for DTC 
in BM was 13.2 (SEM 7.8) and 12.4 (SEM 4.6) in those patients 
without DTC (p=0.91). There was no significant difference 
(p=0.92) in mean miR-21 value between DTC-positive (26.4; 
SEM 8.8) and DTC-negative patients (22.9; SEM 4.97).
Furthermore, to assess independent relationships of DTC in 
BM with tumor miRNA expression, logistic regression analysis 
was performed. OR was adjusted for other covariables, including 
primary tumor site (colorectal vs. non-colorectal), stage (I-III vs. 
IV) and lymph node metastasis (negative vs. positive). However, 
Table IV. Relations of disseminated tumor cells in bone marrow with tumor miRNAs expression: logistic regression analysis. 
 mir-17 miR-20 miR-21
 ---------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------
Groups DTC positive OR 95% CI P-value OR 95% CI P-value OR 95% CI P-value
  N (%)
Global 16 (42.1) 0.947 0.879 1.020 0.148 1.026 0.961 1.095 0.438 0.998 0.976 1.020 0.832
Stage
 I-III   5 (33.3) 1.042 0.847 1.282 0.700 0.970 0.769 1.224 0.800 0.943 0.874 1.019 0.137
 IV 11 (47.8) 0.848 0.680 1.058 0.143 1.035 0.903 1.187 0.618 1.020 0.983 1.058 0.289
Lymph node
 Negative   8 (57.1) 0.218 0.013 3.567 0.285 16.961 0.090 3202.2 0.290 1.022 0.980 1.066 0.315
 Positive   6 (31.6) 0.962 0.797 1.160 0.681 1.117 0.876 1.425 0.373 0.874 0.729 1.049 0.148
Primary tumor site            
 Colon or rectum 10 (35.7) 0.996 0.884 1.122 0.944 0.981 0.847 1.136 0.798 0.997 0.967 1.028 0.849
 Stomach/pancreas   6 (60) 0.711 0.308 1.642 0.424 1.285 0.588 2.809 0.529 1.003 0.964 1.044 0.870
Table V. Multivariate Cox proportional hazard regression analyses for progression-free survival and overall survival. 
 Progression-free survival Global survival
 ------------------------------------------------------------------ ------------------------------------------------------------------
Variable Subset Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Disseminated tumor cells Negative/positive 4.07 1.54 10.73 0.005 3.98 1.39 11.41 0.010
miR-17 expression Down-/up-regulated 2.11 1.29   3.45 0.003 2.62 1.55   4.49 0.000
Stage I-III/IV 5.30 1.59 17.70 0.007 3.97 1.08 14.56  0.037
Surgical resection R0-1/R2 1.10 0.60   2.00 0.766 1.15 0.50   2.21 0.681
Primary tumor Colorectal/non-colorectal 0.16 0.06   0.45 0.000 0.17 0.06   0.53 0.002
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the presence of DTC in BM was, again, not associated with 
miRNA expression (Table IV).
Prognostic significance of DTC and miRNA expression: Cox 
models. We used multivariate Cox regression analysis to inves-
tigate whether the presence of DTC and miRNA expression 
was an independent predictor of progression-free survival and 
overall survival in gastrointestinal cancer patients. The stage, 
extent of surgical resection and location of the primary tumor 
were used as covariates (Table V).
According to Cox multivariate regression analysis, the 
factors associated with a higher risk of PFS events were DTC 
positivity (HR 4.07; p=0.005), miR-17 overexpression (HR 
2.11; p=0.003) and stage IV cancer (HR 5.3; p=0.007). The 
risk of progression was lower in colorectal cancer patients (HR 
0.16; p<0.001).
The presence of DTC in BM was also associated with poor 
overall survival (HR 3.98; p=0.010) in the multivariate model. 
Moreover, the higher expression of miR-17 resulted in a 2.62-
fold increase in the risk of death (p<0.001). In addition, stage 
IV (HR 3.97; p=0.037) was also associated with poor OS. The 
risk of death was lower in colorectal cancer patients (HR 0.17; 
p=0.002).
Discussion
In our study, we examined the presence of DTCs in the BM of 
patients with colorectal, gastric and pancreatic cancer and their 
clinical outcomes. We then investigated the existence of any 
correlation between these findings and the tumor expression 
of selected miRNA. We found that CK-positive bone marrow 
cells and upregulation of the miR-17-92 microRNA cluster in 
the tumor were both significant prognostic markers in gastro-
intestinal cancer patients. Nevertheless, the tumor expression of 
miR-17, miR-20a and miR-21 was not associated with the pres-
ence of disseminated CK-positive cells in the BM.
Although the prognostic relevance of disseminated tumor 
cells in bone marrow is widely accepted in breast cancer (31), 
the clinical and biological significance of finding such microme-
tastasis in GI cancer patients remains controversial. However, 
the clinical value as a prognostic factor of DTC detection in BM 
using CK-based immunocytochemistry in GI cancer patients 
has been suggested in previous studies analyzing colorectal 
(4,10) and gastric cancer (7,8).
Independent prognostic values for progression-free survival 
and global survival were found in our study of DTC detec-
tion using Kaplan-Meier estimates and multivariate analysis. 
Furthermore, the presence of DTC in BM defines a subgroup 
of stage I-III patients with a significantly lower median overall 
survival.
Although the inclusion of patients with different primary 
GI tumors and stages could be considered a limitation of this 
study, we suggest that this pragmatic design accurately reflects 
the patients that attend the oncology clinic. Thus, the prognostic 
value of DTC detection and miRNA quantification has been esti-
mated in a cohort of patients truly representative of those found 
in the clinical setting. In fact, there were no significant differ-
ences among the miRNAs relative expressions levels according 
to location of primary tumor (colorectal or non-colorectal 
cancer). Furthermore, prognostic impact of DTC detection and 
miRNA quantification remain significant in multivariate model 
adjusting for primary tumor site.
In different studies that used immunocytochemistry, 
CK-positive cells were detected in the BM of 16-64% of 
colorectal (13-15), 25-66% of gastric (5-8,13) and 21-61% of 
pancreatic cancer patients (9,32). In the present report, DTC 
were found in 42.1% of patients (35.7% of colorectal and 64.3% 
of gastric and pancreatic cancer patients). Interestingly, and in 
agreement with the results of previous publications (13), the 
detection of DTC was not associated in our study with TNM/
UICC stage, pathological grade, vascular or perineural invasion 
or the extent of surgical resection. Therefore, we hypothesized 
that the presence of cancer cells in the bone marrow may reflect 
the distinct biological properties of a tumor. These unique 
biological characteristics of the primary tumors may influence 
the ability of cancer cells to disseminate in certain distant 
organs and subsequently trigger metastasis formation. Thus, 
combined analyses of the primary tumor histopathology, as 
well as their genetic and transcriptomic backgrounds and DTC 
status, will increase our understanding of invasion and overt 
metastasis development in GI cancer.
At present, little is known about the characteristics of primary 
gastrointestinal tumors that might have a role in the early shed-
ding of tumor cells into the bloodstream and subsequent homing 
to bone marrow. The presence of disseminated carcinoma cells 
in bone marrow in patients with various types of epithelial 
tumors, including colorectal, gastric and pancreatic cancer, is 
not associated with TP53 gene mutations in the primary tumor 
(33). Markers of tumor angiogenesis, such as microvessel counts 
and VEGF-A expression in primary gastric cancer, have been 
correlated with the presence of DTC in bone marrow (34,35). 
A significant association between CXCR4-positive expres-
sion of cancer cells in the primary tumor and the presence of 
CK-positive cells in the bone marrow has been described in 
patients with squamous cell carcinoma or adenocarcinoma of 
the esophagus (36). Tumor expression of the neural cell adhesion 
molecule L1 (CD171) is associated with micrometastatic spread 
and poor outcome in colorectal cancer (37).
Recently, attention has focused on the role of miRNA 
regulation in essential mechanisms for cancer progression and 
metastasis, including invasion, proliferation, cell migration, 
EMT, angiogenesis and apoptosis (17,18,24). Therefore, we 
investigated whether the occurrence of DTC in bone marrow 
was associated with miRNA tumor expression and the related 
potential prognostic value. Furthermore, the stability of miRNAs 
in formalin-fixed, paraffin-embedded tissue and the suitability 
for real-time PCR-based assays, as a gold-standard method for 
quantification, are clearly advantageous for biomarker research 
(38).
Here, tumor overexpression of the miR-17-92 cluster emerged 
as a compelling prognostic indicator in GI cancer. This was 
independently confirmed by a multivariate Cox proportional 
hazard model, which defined miR-17 upregulation as a statisti-
cally significant independent predictor of poor PFS and OS. 
Furthermore, Cox regression models showed that increasing 
continuous values for miR-20a and miR-17 were both associated 
with the risk of progression and death in stage I-III patients.
Nonetheless, deregulated expression of the miRNAs was 
not associated with any of the clinicopathological tumor 
parameters investigated or with the detection of CK-positive 
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cells in the BM. A significant association was observed only 
between high expression of miR-17 and CEA level.
Preclinical and translational studies have established the 
oncogenic role of the miR-17-92 cluster in several hematological 
and solid tumors (24,25). All six members of the mir-17-92 
polycistron on chromosome 13 (miR-17, miR-18a, miR-19a, 
miR-20a, miR-19b-1 and miR-92a-1) are some of the highest-
overexpressed miRNAs in several cancer types (25,29).
It appears reasonable to assume that the prognostic impact of 
the up-regulation of miR-17 and miR-20a in GI cancer is attribut-
able in part to the mechanistic relevance of their target genes (40). 
mir-17 and miR-20a down-regulate the activating members of 
the E2F family of transcription factors (E2F1, E2F2, and E2F3) 
and the cyclin-dependent kinase inhibitor CDKN1a/p21, which 
are regulators of the G1-to-S-phase transition in the cell cycle. 
Furthermore, the apoptosis inducer BIM and the proto-oncogene 
LRF, implicated in senescence, are also under the control of the 
miR-17-92 cluster (40). A recent report has identified hypoxia-
inducible factor (HIF)-1A as a novel direct target of miR-17-5p 
and miR-20a (41). Furthermore, overexpression of the miR-17-92 
cluster markedly inhibits hypoxia-induced apoptosis in colon 
cancer cell lines through the regulation of p53-mediated tran-
scriptional repression (42). Recent data suggest that miR-17-5p 
and miR-20a directly control the expression of the type II TGFβ 
receptor in colorectal cancer progression, inhibiting the tran-
scription of individual TGFβ-responsive genes and indirectly 
stimulating angiogenesis through inhibition of a wide repertoire 
of anti-angiogenic factors (43).
Nevertheless, studies on miR-17-92 cluster deregulation in GI 
cancer in the clinical setting and its potential prognostic impact 
are limited. Altered expression of miR-17-5p is associated (44) 
with vascular invasion and LOH in the TP53 region in a series 
of colorectal cancer patients. A trend between poor disease-free 
survival and upregulation of miR-17-5p has also been observed, 
but only in stage I-II patients. In that series, downregulation of its 
paralog miR-106a was independently associated with DFS and 
OS (44). Contradictory results in relation to miR-106a have been 
reported elsewhere (19). In that study, in an analysis designed to 
identify whether any of the overexpressed miRNAs in colorectal 
cancer identified by microarray experiments are associated with 
poor survival, up-regulation of miR-20a, miR-21, miR-106a, 
miR-181b and miR-203 was significant in the training cohort. 
However, only miR-21 retained the prognostic impact in the 
validation cohort. Tumors with high expression of miR-21 were 
associated with poor survival outcome and poor response to 
adjuvant chemotherapy independent of staging and other clinical 
covariates (19). Likewise, in gastric cancer patients, miR-21 was 
overexpressed and selected in the progression signature but not 
in the survival signature (45).
In our study, increased miR-21 level was found in 90.6% of 
tumors, consistently with previous studies investigating patients 
with colon (25,27,39), gastric (21,39,45,46) and pancreatic 
(22,23,29) adenocarcinomas. However, we did not find any 
significant associations between miR-21 level and the clinical 
and pathologic characteristics, in line with recently reported 
results (47). Likewise, in our series, expression of miR-21 was 
not associated with any of the clinical outcomes analyzed.
miR-21, acting as an oncogene (48), targets the products 
of several genes relevant to cancer progression and metastasis, 
including PDCD4, SPRY, PTEN and TPM1. Recent data suggest 
that miR-21 induces a paradoxical negative regulation of cell cycle 
progression in hypoxic colon cancer models, through a Cdc25a 
protein phosphatase-dependent mechanism (49). Interestingly, 
in situ hybridization results indicate that miR-21 is located 
primarily in the stromal compartment of the tumors (50). These 
data suggest a set of connections between tumor cells and their 
microenvironment, where the net effect of a particular miRNA 
might be variable, in a cellular context-dependent manner.
Furthermore, technical differences could explain apparently 
contrasting results. In fact, in the study reported by Schepeler 
et al (51), there was no correlation between miR-21 expres-
sions data obtained with real-time RT-PCR as compared to 
data obtained with microarray with probes designed against the 
mature form. Also, the limited numbers of patients included in 
the studies, including ours, make the data more susceptible to 
stochastic effects.
When we considered the different reports about the poten-
tial prognostic relevance of miRNA expression in GI cancer, 
a considerable degree of inter-study heterogeneity was noted. 
Differences in the detection and quantification methods (micro-
arrays, qRT-PCR), types and numbers of miRNAs evaluated 
(pre-miRNA or mature form, expression profile, single marker), 
and sample source (FFPE, deep-frozen, specimen microdissec-
tion), as well as in the clinicopathological data of the included 
patients, ought to be considered as potential sources of hetero-
geneity.
In conclusion, our study suggests that the presence of 
CK-positive cells in the bone marrow and the upregulation of the 
miR-17-92 cluster in the tumor were both significant but inde-
pendent prognostic markers in gastrointestinal cancer patients. 
These results will require validation in independent and large 
sample sets before firm conclusions can be reached.
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